News
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...
When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds.
A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. View (VRTX) real-time stock price, chart, news, analysis, analyst reviews and more.
StockStory.org on MSN4d
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings CallVertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...
In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...
While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...
Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...
This was the stock's second consecutive day of gains.
7d
Clinical Trials Arena on MSNVertex presents data from Phase I/II stage of trial for type 1 diabetesVertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results